Research programme: CRISPR based gene therapeutics - Incisive Genetics
Latest Information Update: 28 Oct 2024
At a glance
- Originator Incisive Genetics
- Developer Incisive Genetics; University of British Columbia
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Eye disorders; Huntington's disease; Neurological disorders
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Eye-disorders in Canada
- 28 Oct 2024 No recent reports of development identified for preclinical development in Huntington's-disease in Canada
- 28 Oct 2024 No recent reports of development identified for preclinical development in Neurological-disorders in Canada